Applied Genetic Technologies Corporation
ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF GENETIC HEARING LOSS
Last updated:
Abstract:
Described herein are optimally-modified GJB2 cDNA and associated genetic elements for use in recombinant adeno-associated virus (rAAV)-based gene therapy for the treatment of genetic hearing loss.
Status:
Application
Type:
Utility
Filling date:
30 Sep 2020
Issue date:
1 Apr 2021